BCLSI
TSVT

Bain Capital Life Sciences Investors’s 2seventy bio TSVT Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio TSVT Stock Details TSVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,331,801
Closed -$5.69M – 29
2023
Q4 		$5.69M Sell
1,331,801
-77,100
-5% -$237K 0.55% 24
2023
Q3 		$5.52M Hold
1,408,901
– – 0.62% 27
2023
Q2 		$14.3M Hold
1,408,901
– – 1.47% 21
2023
Q1 		$14.4M Hold
1,408,901
– – 1.8% 19
2022
Q4 		$13.2M Hold
1,408,901
– – 1.48% 19
2022
Q3 		$20.5M Hold
1,408,901
– – 2.45% 15
2022
Q2 		$18.6M Hold
1,408,901
– – 2.18% 13
2022
Q1 		$24M Buy
1,408,901
+1,229,508
+685% +$20.9M 2.33% 12
2021
Q4 		$4.6M Buy
+179,393
New +$5.6M 0.36% 31

Other funds holding TSVT

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Bain Capital Life Sciences Investors's TSVT Position: Q1 2024 in Review

Bain Capital Life Sciences Investors sold out of 2seventy bio (TSVT) in Q1 2024, closing a stake of 1,331,801 shares — an estimated $5.69M sold.

Bain Capital Life Sciences Investors first reported a position in TSVT in Q4 2021 and held it in 9 quarters. The position peaked at $24M in Q1 2022. 117 funds tracked by Wall St. Rank hold TSVT as of Q1 2024.

  • Bain Capital Life Sciences Investors reported no remaining 2seventy bio position as of Q1 2024 after selling out during the quarter.
  • Bain Capital Life Sciences Investors sold 1,331,801 2seventy bio shares in Q1 2024, an estimated $5.69M.
  • Bain Capital Life Sciences Investors first reported a position in 2seventy bio in Q4 2021 and held it in 9 quarters.
  • Bain Capital Life Sciences Investors's 2seventy bio position peaked at $24M in Q1 2022.
  • 117 funds tracked by Wall St. Rank held 2seventy bio as of Q1 2024.

Based on Bain Capital Life Sciences Investors's 13F filing for Q1 2024, filed 15 May 2024.